Business Context and Reporting Period
Company: Accendra Health, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: May 11, 2026
Event: Entry into a Material Definitive Agreement (Commitment and Consent Letter) regarding a comprehensive debt restructuring and refinancing transaction.
Key Financial Metrics and Transaction Details
This filing details a proposed capital structure reorganization rather than reporting standard operating financial results (revenue, profit, cash flow). Key financial figures related to the transaction include:
- New Money First Lien Notes: $326.25 million aggregate principal amount of 9.000% Senior Secured First Lien Notes due 2032.
- Backstop Commitment: Backstop Parties agreed to purchase up to $261.0 million of New Money First Lien Notes at par, plus up to an additional $65.25 million if unsubscribed, in exchange for a 3.50% cash fee.
- New Revolving Credit Facility: $300.0 million facility due in 2030 (with a springing maturity provision).
- Existing Debt Targeted: 4.500% Senior Notes due 2029 (approx. 100% held by consenting parties) and 6.625% Senior Notes due 2030 (approx. 83% held by consenting parties).
- Asset Sale Waiver: Consent obtained for asset sales with net cash proceeds up to $400.0 million without mandatory prepayment.
Material Changes and Proposed Amendments
The Company is executing Exchange Offers and Consent Solicitations to replace existing debt with new instruments and amend indentures. Material changes include:
- Debt Exchange: Existing Notes will be exchanged for new 9.000% First Lien Notes and 9.750% Second Lien Notes due 2033.
- Covenant Relief: Proposed amendments will eliminate substantially all affirmative and negative covenants, remove certain events of default, and modify merger/consolidation provisions in the Existing Notes Indentures.
- Term Loan Modifications: Conforming Term Loan Credit Agreement covenants to the new Revolving Credit Facility and waiving mandatory prepayment on asset sales.
- Use of Proceeds: Proceeds from the New Money Notes Issuance and cash on hand will be used to repay outstanding borrowings under the Term "A" facility and the Existing Revolving Credit Facility.
Guidance, Risks, and Contingencies
Management Commentary: The transaction is designed to provide financial flexibility and extend maturities. The Commitment Letter terminates on the earlier of the final closing date or June 30, 2026.
Risks and Contingencies:
- Completion Risk: The Offers and Consent Solicitations are subject to numerous conditions and may not be completed as contemplated or at all.
- Financial Impact: Failure to complete the transactions on favorable terms could materially adversely affect the Company's financial condition.
- Forward-Looking Statements: Actual results may differ due to market conditions, termination of the Commitment Letter, or disruption of management attention.
- Regulatory Status: The New Notes are not registered under the Securities Act and cannot be offered in the U.S. except pursuant to exemptions.
Investor Verification Checklist
- Verify the final terms of the Exchange Offers and Consent Solicitations in the confidential Offering Memorandum.
- Confirm the percentage of Existing Notes tendered and consents received to ensure the transaction thresholds are met.
- Review the specific "springing maturity" terms of the new $300 million Revolving Credit Facility.
- Assess the impact of the 3.50% cash fee paid to Backstop Parties on immediate liquidity.
- Monitor the status of the $400 million asset sale waiver and any related proceeds.